Home

Watch Aerpio’s Joseph Gardner on the Big Biz Show

August 27, 2020

August 13, 2020

Aerpio Pharmaceuticals is a biopharmaceutical company focused on leveraging Tie2 activation for ocular disease and vascular stabilization.

Our lead product candidate, razuprotafib (AKB-9778), is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open angle glaucoma. A Phase 2 trial in patients with open angle glaucoma/ocular hypertension is ongoing with top line data anticipated in Q4 2020.

The vascular stabilizing effects of subcutaneously administered razuprotafib are being investigated in two Phase 2 trials in patients with COIVD-19 (I-SPY-COVID-19 and RESCUE) which will read out in 2021.

The Company is also evaluating development options for subcutaneously administered razuprotafib and ARP- 1536, a humanized Tie2-activating monoclonal antibody, in the treatment of diabetic vascular complications including nephropathy.

ARP-1536 is also in preclinical development for intravitreal administration as an adjunct to anti-VEGF therapy in patients with sight threatening retinopathies i.e. diabetic macular edema (DME) and wet age-related macular degeneration (wetAMD).

The Company’s third asset is a bispecific antibody that is designed to inhibit VEGF and activate Tie2. This bispecific antibody has the potential to be an improved treatment for DME and wet age-related macular degeneration via intravitreal injection and cancer via systemic administration.

Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class orally bioavailable, gut targeted small molecule hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor. GB004 is being developed by AKB-4924’s exclusive licensor, Gossamer Bio, Inc. (Nasdaq: GOSS), in return for upfront payments totaling $35 million, future potential development, regulatory, and sales milestones of up to $90 million, and royalties on worldwide net sales.

Press Releases

Topline Data Expected 4Q 2020 CINCINNATI , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO), a biopharmaceuti ...

Sep 15, 2020

SAN FRANCISCO and CINCINNATI, Sept. 1, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals , Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap He ...

Sep 01, 2020

Initiated a Phase 2 Open Angle Glaucoma Trial; Recruiting Ahead of Schedule Announced Partnership with I-SPY to Participate in a Clinical Trial to Tre ...

Aug 12, 2020

CINCINNATI , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ...

Aug 10, 2020

CINCINNATI , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through th ...

Aug 04, 2020

CINCINNATI , June 24, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ...

Jun 24, 2020

CINCINNATI , June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the publi ...

Jun 08, 2020

CINCINNATI , June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ...

Jun 08, 2020

SAN FRANCISCO and CINCINNATI , May 27, 2020 /PRNewswire/ --  Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare C ...

May 27, 2020

Aerpio Received an Immediate Payment of $15 million CINCINNATI , May 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ...

May 12, 2020

Razuprotafib (formerly known as AKB-9778) Phase 2 Open Angle Glaucoma Trial on Track for Third Quarter Start CINCINNATI , May 07, 2020 (GLOBE NEWSWIR ...

May 07, 2020

Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 20 ...

Mar 16, 2020

CINCINNATI , March 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compoun ...

Mar 12, 2020

Data presented at the 9 th Annual Glaucoma 360 New Horizons Forum CINCINNATI --(BUSINESS WIRE)--Feb. 7, 2020-- Aerpio Pharmaceuticals, Inc. (Nasdaq: A ...

Feb 07, 2020

CINCINNATI --(BUSINESS WIRE)--Jan. 8, 2020-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...

Jan 08, 2020

CINCINNATI --(BUSINESS WIRE)--Nov. 7, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...

Nov 07, 2019

CINCINNATI --(BUSINESS WIRE)--Oct. 21, 2019-- Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compoun ...

Oct 21, 2019

  CINCINNATI --(BUSINESS WIRE)--Oct. 10, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compoun ...

Oct 10, 2019

CINCINNATI --(BUSINESS WIRE)--Aug. 8, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...

Aug 08, 2019

CINCINNATI --(BUSINESS WIRE)--Jun. 10, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...

Jun 10, 2019

On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in the Second Quarter of 2 ...

May 09, 2019

Data presented during “The Role of the Tie2 Pathway in Ocular Disease” symposium at the Association for Research in Vision and Ophthalmology (ARVO ...

May 02, 2019

Data to be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting CINCINNATI --(BUSINESS WIRE)--Apr. 25, 201 ...

Apr 25, 2019

CINCINNATI --(BUSINESS WIRE)--Apr. 5, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...

Apr 05, 2019

TIME-2b Study Did Not Meet the Primary Endpoint of 2-Step Reduction in DRSS Score Conference Call and Webcast Today, March 18th at 8:30 a.m. EDT CINCI ...

Mar 18, 2019

Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) Expe ...

Mar 05, 2019

CINCINNATI --(BUSINESS WIRE)--Feb. 26, 2019-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds ...

Feb 26, 2019

CINCINNATI --(BUSINESS WIRE)--Jan. 17, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...

Jan 17, 2019

CINCINNATI --(BUSINESS WIRE)--Nov. 8, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...

Nov 08, 2018

TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track Conference Call and Webcast Today, November 7 th at 8:30 a.m. EST CI ...

Nov 07, 2018

CINCINNATI --(BUSINESS WIRE)--Oct. 31, 2018-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds ...

Oct 31, 2018

CINCINNATI --(BUSINESS WIRE)--Oct. 25, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-cl ...

Oct 25, 2018

CINCINNATI --(BUSINESS WIRE)--Sep. 24, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-cl ...

Sep 24, 2018

CINCINNATI --(BUSINESS WIRE)--Aug. 30, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-cl ...

Aug 30, 2018

TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track; Data in Q2 2019 Partnership for AKB-4924 with Gossamer Bio ...

Aug 14, 2018

CINCINNATI --(BUSINESS WIRE)--Aug. 7, 2018-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on advancing first-in-cla ...

Aug 07, 2018

CINCINNATI --(BUSINESS WIRE)--Jun. 26, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”) today announced that its common stock will begi ...

Jun 26, 2018

CINCINNATI --(BUSINESS WIRE)--Jun. 25, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”) today announced that it intends to sell, subjec ...

Jun 25, 2018

CINCINNATI & SAN DIEGO --(BUSINESS WIRE)--Jun. 25, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced an exclusive global license a ...

Jun 25, 2018

CINCINNATI --(BUSINESS WIRE)--May 31, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-clas ...

May 31, 2018

CINCINNATI --(BUSINESS WIRE)--May 22, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced the initiation of dosing in a Phase 1a, multip ...

May 22, 2018

CINCINNATI --(BUSINESS WIRE)--May 15, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-clas ...

May 15, 2018

TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track CINCINNATI --(BUSINESS WIRE)--May 15, 2018-- Aerpio Pharmace ...

May 15, 2018

CINCINNATI --(BUSINESS WIRE)--May 4, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class ...

May 04, 2018

CINCINNATI --(BUSINESS WIRE)--Mar. 20, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in- ...

Mar 20, 2018

CINCINNATI --(BUSINESS WIRE)--Mar. 15, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in- ...

Mar 15, 2018

TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call and Webcast Today, March 13 th at 8:30 a.m. ...

Mar 13, 2018

CINCINNATI --(BUSINESS WIRE)--Mar. 7, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-cl ...

Mar 07, 2018

CINCINNATI --(BUSINESS WIRE)--Mar. 6, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-c ...

Mar 06, 2018

CINCINNATI --(BUSINESS WIRE)--Feb. 28, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-cla ...

Feb 28, 2018

CINCINNATI --(BUSINESS WIRE)--Feb. 9, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB:ARPO) (“ Aerpio ”), a biopharmaceutical company focused on adva ...

Feb 09, 2018

CINCINNATI --(BUSINESS WIRE)--Dec. 18, 2017-- Aerpio Pharmaceuticals , Inc. (OTCQB: ARPO) (“ Aerpio ”), a biopharmaceutical company focused on ad ...

Dec 18, 2017

CINCINNATI --(BUSINESS WIRE)--Nov. 14, 2017-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-cl ...

Nov 14, 2017

Strengthened Senior Leadership Team with the Appointment of Stephen Hoffman , M.D., Ph.D., as Chief Executive Officer Effective December 1, 2017 TIME- ...

Nov 13, 2017

CINCINNATI --(BUSINESS WIRE)--Oct. 10, 2017-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-cl ...

Oct 10, 2017

Commenced Trading on the OTCQB ® Market Continue to Dose Patients in the TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy CIN ...

Aug 14, 2017